Citations

SLC26A9 is a Cl - channel and electrogenic Cl - -HCO 3 ‑ exchanger found in several human epithelia, including the lung, intestine / GI tract, and kidney. SLC26 proteins are defined by a C-terminal, cytoplasmic sulfate transporter / anti-σ-domain (STAS). In mammals, several STAS domains have protein-protein interactions with the regulatory-region of CFTR (R-CFTR), the Cl - channel associated with cystic fibrosis. However, the functional consequences, i.e., regulatory effects (up/downregulation), of STAS-to-R-CFTR binding seem to differ by SLC26 member. Our prior work showed that the SLC26A9:CFTR interaction decreases SLC26A9 channel and exchange activity. If SLC26A9-STAS was replaced with SLC26A6-STAS, no inhibition of SLC26A9 conductance occurred when interacting with R-CFTR (PMID 19643730). Complete deletion of SLC26A9-STAS removed Cl - conductance. Thus, we hypothesized that a disordered loop within STAS is the likely interaction area, and therefore deleted this STAS-disordered loop (ΔLoop) to test this region’s functionality. We used a voltage clamp to measure Cl - currents (IV; conductance G calculated) in Xenopus laevis oocytes (n=10 / construct) injected with cRNA of ΔLoop and subcomponent areas of SLC26A9. Each construct contained a 3xFLAG tag such that stained oocytes from these constructs allowed determination of membrane expression. ΔLoop has three subregions: K/R rich, Middle, S/T rich. Both ΔLoop and ΔLoop(K/R) increase Cl - currents (and conductance) by 5x greater comparted to wild-type SLC26A9. Five amino acid extension of ΔLoop (N- or C-terminal) produces Cl - currents equivalent to ΔLoop deletion. However, 10 amino acid extension of ΔLoop (N- or C- direction) produces currents equivalent to WT-SLC26A9. Membrane localization indicates that ΔLoop and regional deletion constructs have similar membrane abundance to WT, while boundary deletions inhibit channel trafficking to the membrane. As ΔLoop(S/T) slightly increased conductance, the ordered S/T-rich motif [T 620 SVSYITFS 628 ] was examined for possible phosphorylation effects by serial alanine substitution. Each alanine substitution in the S/T-rich motif decrease SLC26A9 Cl - conductance vs WT-SLC26A9. However, for S623A the conductance decrease was due to minimal plasma membrane expression rather than apparent change of channel activity. Together these data suggest that the disordered loop is multifaceted and can maintain low conductance (autoinhibition) or by potential phosphorylation. As cystic fibrosis (CF) results from loss-of-function, trafficking or degradation mutations, the robust Cl - conductance from elimination of SLC26A9 autoinhibitory, disordered loop, presents an opportunity to supplement or replace Cl - conductance in CF tissues and potentially patients. R25-DK101405 This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.

Abstract Cerium oxide (CeO 2 ) nanozymes have emerged as a novel class of nanozyme materials distinguished by their tunable valence states (Ce 3+ /Ce 4+ ) and abundant surface oxygen vacancies (OVs), demonstrating exceptional chemical stability, cost‐effectiveness, and scalable manufacturability. Precise control of reaction temperature or implementation of carrier‐mediated crystal growth strategies effectively enhances nanoparticle dispersion and mitigates aggregation. This review systematically summarizes recent advancements in CeO 2 nanozymes: First, it elaborates on cutting‐edge synthetic methodologies, encompassing self‐supported strategies (calcination, hydrothermal, and sol–gel) and carrier‐mediated approaches (small‐molecule compounds, macromolecular compounds, and nanomaterials), with comparative analysis of their respective merits and limitations. Second, the catalytic mechanism is comprehensively elucidated, particularly focusing on the modulation of electron transfer kinetics and surface adsorption energies in metal/nonmetal hybrid systems. By optimizing oxygen vacancy concentration to regulate Ce 3+ /Ce 4+ redox cycling dynamics, significant enhancement in redox efficiency and catalytic stability can be achieved, enabling precise enzyme‐like activity regulation. Furthermore, the review comprehensively summarizes breakthrough applications in multidimensional biomedical fields, including precision tumor therapy, intelligent antibacterial systems, inflammatory microenvironment regulation, and ultrasensitive biosensing. This work establishes a theoretical framework for structure‐activity relationship‐guided rational design of high‐performance CeO 2 nanozymes and delineates their potential translational applications in precision medicine.

SUMMARY Tau aggregates propagate through the brain in a prion-like manner in Alzheimer’s disease (AD) and other tauopathies, but the molecular identity and functional partners of the seeding-competent Tau species remain poorly defined. Here, we present an unbiased proteomic profiling of a high-molecular-weight (HMW) Tau-seed isolated from AD patient brains. We contrast this interactome with that of a biochemically similar, seeding-incompetent HMW-Tau species from age-matched healthy controls. Despite comprising less than 5% of total Tau in the brain, Tau-seed associates with a distinct set of proteins enriched in synaptic, mitochondrial, and vesicle-trafficking functions. Cross-species functional screening in Drosophila and mouse models identifies interactors that modulate Tau toxicity and seeding. Spatially resolved analysis of postmortem AD brains reveals heterogenous co-deposition of these proteins with Tau aggregates, suggesting functionally distinct Tau-seed complexes. Together, this dataset provides a framework for understanding selective Tau-seed toxicity and identifies candidate regulators of Tau propagation with therapeutic potential.

Background The effectiveness of endovascular thrombectomy (EVT) for low Alberta Stroke Program Early CT score (ASPECTS) stroke patients with occlusion of the second segment of the middle cerebral artery (M2) is unclear. Methods This was a multicenter retrospective study. Patients with M1 or M2 occlusions and low ASPECTS (<6) who underwent successful EVT (modified treatment in cerebral ischemia score of 2b or higher) were included. Primary outcome was futile EVT reperfusion (defined as 90-day modified Rankin scale of 5 or 6). Other outcomes of interest include acceptable outcomes (modified Rankin scale of 3 or less) and intracranial hemorrhage (ICH), and all-cause 90-day mortality. Outcomes for M1 patients were compared to M2 patients with multivariable logistic regression models accounting for potential confounders. Results 173 patients with M1 or M2 occlusions and low ASPECTS (<6) who underwent successful EVT were identified. After multivariable adjustments, M2 patients had significantly higher odds of futile reperfusion (OR 5.48 [95%CI 1.91 to 15.7], p = 0.002), lower odds of acceptable outcomes (OR 0.33 [95%CI 0.12 to 0.89], p = 0.028), and higher odds of all-cause mortality (OR 4.90 [95%CI 1.65 to 14.5], p = 0.004). These findings suggest that EVT's efficacy for low-ASPECTS stroke patients may be diminished for patients with M2 occlusions. M2 occlusion was not significantly associated with ICH. Conclusions Among low-ASEPCTS stroke patients who underwent successful EVT, those with M2 occlusions had significantly higher odds of poor outcome compared to those with M1 occlusions.

BACKGROUND AND OBJECTIVES: It remains unclear whether decompressive craniectomy (DC) is beneficial in patients who suffer symptomatic intracerebral hemorrhage (sICH) after acute ischemic stroke (AIS). We sought to study the effect of DC on functional outcomes in patients with sICH after AIS who underwent mechanical thrombectomy (MT). METHODS: Patients with AIS from anterior circulation large vessel occlusion who underwent MT and subsequently developed sICH were identified from the Stroke Thrombectomy and Aneurysm Registry database. The primary outcome was acceptable 90-day functional neurological outcome, defined as modified Rankin scale (mRS) 0-3. Multivariable logistic regression and propensity-score matching were used to identify and quantify risk factors. RESULTS: Of 464 patients identified with sICH after AIS after MT, 97 patients (20.9%) underwent DC. Patients who underwent DC were more likely to be female ( P < .001), younger ( P < .001), have a measured medical comorbidity, have higher baseline mRS ( P = .02), and have higher-grade hemorrhages ( P = .01). At 90 days, 14% of patients had the primary outcome of mRS 0-3 and 56% had died. The primary outcome was observed in 11 patients who underwent DC (11%) and 55 (15%) of those without DC (odds ratio [OR] 0.7, 95% CI 0.4-1.4, P = .40). DC did not affect mRS shift at 90 days ( P = .10) but was associated with lower mortality (OR 0.5, 95% CI 0.3-0.8, P = .01). Multivariable analysis demonstrated that DC decreased the odds of primary outcome (adjusted OR 0.2, 95% CI 0.02-0.9, P = .045), but did not affect mortality ( P = .94), mRS shift ( P = .50), or length of stay ( P = .90). Propensity-matched analysis similarly demonstrated that non-DC patients were more likely to achieve the primary outcome (24% vs 8%, P = .045). CONCLUSION: In patients with sICH after AIS after MT, those selected for DC had less favorable outcomes and similar rates of mortality at 90 days.